• Neovascular (wet) age-related macular degeneration.
• Diabetic macular edema.
• Macular edema following retinal vein occlusion.

Contraindicated in:

• Hypersensitivity
• Ocular/periocular infections
• Active intraocular inflammation.

Use Cautiously in:

• OB: Safety not established in pregnancy
• Lactation: Safety not established in lactation
• Women of reproductive potential
• Pedi: Safety and effectiveness not established in children.

CV: MI, STROKE.

EENT: cataract, ↑ intraocular pressure, ↑ lacrimation, conjunctival hemorrhage, endophthalmitis, eye irritation, eye pain, intraocular inflammation, retinal detachment, retinal pigment epithelial tear, retinal vascular occlusion, retinal vasculitis, vitreous floater.
Misc: hypersensitivity reactions.

Drug-Drug:

• None reported

• Solution for intravitreal injection (vials and prefilled syringes): 120 mg/mL;

Neovascular (wet) Age-Related Macular Degeneration

• Intravitreal (Adults): 6 mg every 4 wk for four doses. Subsequent doses are individualized based on optical coherence tomography and visual acuity evaluations performed 8 and 12 wk later, and are administered as one of the following regimens: Every 8-wk regimen: 6 mg on Weeks 20, 28, 36, and 44; or Every 12-wk regimen: 6 mg on Weeks 24, 36, and 48; or Every 16-wk regimen: 6 mg on Weeks 28 and 44. Some patients may require dosing every 4 wk following the initial 4 doses.

Diabetic Macular Edema

• Intravitreal (Adults): Administer one of the following regimens: Fixed interval regimen: 6 mg every 4 wk for six doses, followed by 6 mg every 8 wk; or Variable interval regimen: 6 mg every 4 wk for at least four doses, followed by 6 mg every 4–16 wk (based on optical coherence tomography and visual acuity evaluations).

Macular Edema Following Retinal Vein Occlusion

• Intravitreal (Adults): 6 mg every 4 wk for 6 mo.

Vabysmo

• Inhibits vascular endothelial growth factor-A (VEGF-A), preventing the binding of endogenous VEGF-A, resulting in decreased endothelial proliferation, vascular leakage, and new vessel formation. Also inhibits angiopoietin-2, which promote vascular stability and protects blood vessels from the effects of VEGF-A.

• Decreased progression of visual loss.

Therapeutic Classification: ocular agents

Pharmacologic Classification: vascular endothelial growth factor antagonists, monoclonal antibodies

Absorption: Intravitreal injection results in complete local bioavailability. Very low serum levels are achieved.

Distribution: Unknown.

Metabolism/Excretion: Catabolized in lysosomes to small peptides and amino acids that are excreted renally.

Half-life: 7.5 days.

• Advise patient to notify ophthalmologist immediately if eye becomes red, sensitive to light, painful, or develops a change in vision.
• May cause temporary visual disturbances. Caution patient to avoid driving or other activities requiring good eyesight until response to medication is known.
• May cause fetal harm. Advise females of reproductive potential to use highly effective contraception during and 3 mo after last dose. Advise females of reproductive potential to notify health care professional promptly if pregnancy is planned or suspected or if breastfeeding. May impair fertility.

far-IK-i-mab